Is Telisotuzumab already included in the medical insurance system?

Telisotuzumab (Telisotuzumab vedotin) is an antibody conjugate drug targeting c-Met. It has just been approved by the United States in 2025 May pan>FDA's accelerated approval for the treatment of patients with non-small cell lung cancer (NSCLC) with high expression of c-Met, especially those who have developed resistance to previous systemic treatments. As the world's first antibody-conjugated drug specifically targeted at patients with high c-Met protein expression, this drug has attracted high attention in the field of targeted therapy and has become one of the important candidate drugs that many countries are focusing on whether to include in medical insurance.

As of now, terituzumab has not been officially launched in China, and therefore has not been included in China's national medical insurance directory. According to the current medical insurance policy, drugs must be registered and approved in China and go through the national medical insurance negotiation process in order to be included in the medical insurance. And Telisotuzumab has just been launched overseas, and there is no clear domestic listing or review information, which means that domestic patients are temporarily unable to obtain the drug through medical insurance reimbursement, and can only rely on overseas drug purchases or participation in overseas clinical trials to obtain drug opportunities.

In the United States, although the drug has not yet been included in the federal health insurance program, the company AbbVie has launched a variety of patient assistance programs, such as the myAbbVie Assist program, which provides free medication support to uninsured patients, and some commercially insured patients can significantly reduce their out-of-pocket costs through co-payment assistance programs. However, most of these support programs are only available to patients in the United States and have limited help for overseas users. Price is still one of the main barriers to access.

Taken together, terituzumab has not yet entered the medical insurance system of any country, mainly because its time on the market is still short and it is still in the early promotion stage. For domestic patients who are concerned about this drug, they should pay close attention to its registration progress and medical insurance negotiation arrangements with the China Center for Drug Evaluation. At the same time, you can communicate with your oncologist whether you have high c-Met expression characteristics to decide whether it is worth trying to use the drug through cross-border medical treatment.

Reference materials:https://www.drugs.com/